Nurix Therapeutics (NRIX) Stock: Buy, Sell, or Hold?
NRIX - Nurix Therapeutics, Inc. Common stock
$26.02
-0.08 (-0.31%)
▼
5d:
+9.93%
30d:
+1.36%
90d:
+9.6%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Oct 08, 2026
0d
Get Alerted When NRIX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: NRIX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: NRIX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: NRIX is currently trading at $26.02, which is considered extended relative to its 30-day fair value range of $22.76 to $25.28.
Technical Outlook: Technically, NRIX is in a uptrend. The price is approaching resistance at $26.34. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: NRIX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $34.50 (+32.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NRIX is in a uptrend. The price is approaching resistance at $26.34. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: NRIX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $34.50 (+32.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$22.76 -
$25.28
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 32.6% below Wall St target ($34.50)
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$22.76 -
$25.28
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$21.23
Resistance Level
$26.34
Current Trend
Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-20.40
Wall Street Target
$34.50
(+32.6%)
Revenue Growth (YoY)
8426.3%
Profit Margin
42.0%
Share & Embed Analysis
Last updated: October 22, 2026 6:29 AM ET
Data refreshes hourly during market hours. Next update: 7:29 AM
Data refreshes hourly during market hours. Next update: 7:29 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NRIX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 72 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 70 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 76 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 51 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 69 BUY |
